Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Demographics (2)
- AGE - Subject age at enrollment (phv00555913.v1.p1)
- SEX - Biological sex (phv00555907.v1.p1)
Disease Events (1)
- AFFECTION_STATUS - Case control status of the subject for HPV-associated squamous cell carcinoma (phv00555911.v1.p1)
Race and Ethnicity (1)
- RACE - Self-reported race (phv00555912.v1.p1)
Other (13)
- ANALYTE_TYPE - Analyte type (phv00555916.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00555915.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00555906.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00555918.v1.p1)
- IS_TUMOR - Tumor status (phv00555917.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Whether sample is primary tumor, metastasis, or transformed cell line (phv00555919.v1.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00555920.v1.p1)
- SAMPLE_ID - Sample ID (phv00555914.v1.p1)
- SAMPLE_ID - Sample ID (phv00555909.v1.p1)
- SUBJECT_ID - Subject ID (phv00555910.v1.p1)
- SUBJECT_ID - Subject ID (phv00555905.v1.p1)
- SUBJECT_ID - Subject ID (phv00555908.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00555921.v1.p1)